SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is facing intense downward pressure driven by a mix of broader SaaS sector volatility and aggressive short-selling as investors debate the impact of AI competition on its long-term moat. While the community remains deeply divided between those viewing the current price as a deep-value buying opportunity and those fearing further dilution from upcoming lockup expirations and insider sales.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a veteran parody project that has evolved from a 2011 BitcoinTalk forum joke into an on-chain meme asset on Solana. The community is actively debating its potential as the original meme coin, drawing comparisons to Bitcoin while leveraging its long-standing lore to attract holders who are positioning for a speculative long-term breakout.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is currently at the center of a heated debate over whether AI disruption via tools like Anthropic represents a fatal structural threat to legacy SaaS providers or a temporary, sentiment-driven repricing opportunity. Community members remain deeply divided between short-sellers anticipating a permanent valuation collapse and bulls who argue that major software incumbents are oversold and fundamentally resilient, leading to high-volume institutional buying and significant volatility.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is experiencing high volatility as shareholders react to a significant earnings miss and the company's first quarterly report under CEO Greg Abel. Investors are actively debating the company's massive cash pile, its lack of dividend payments, and whether recent performance signals a strategic decline or an impending opportunity for the new leadership to aggressively deploy capital.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) is currently at the center of a heated debate between retail traders who view it as an unstoppable "money machine" fueled by insatiable AI infrastructure demand and skeptics pointing to extreme valuation premiums and potential technical divergences. While bullish participants highlight the sector's leadership role and resilient price action, a vocal cohort of bears remains focused on the potential for a sharp correction as they monitor key support levels and signs of overextension.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management systems, as well as other tools, integrations, and native payment solutions. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot is facing intense selling pressure as investors grapple with concerns that generative AI and agentic platforms could disrupt traditional SaaS business models and drive down demand for seat-based licensing. While many analysts maintain buy ratings and emphasize the company's strong fundamentals, the stock is struggling to find a bottom as the market remains skeptical about the long-term impact of AI on the software sector's growth potential.

Maulcoin

Maulcoin is trending as its community aggressively rallies to regain market momentum and push the ticker back onto major trading platforms. Supporters are actively engaging in social media raids and liquidity-focused community building to drive visibility for what they describe as a long-term, anti-rug project.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is seeing significant volatility and intense community debate following a preliminary Q1 revenue update that signaled record shipments and automation progress. Traders remain sharply divided, with bulls pointing to insider buying and technical accumulation as evidence of a bottom, while bears focus on product reliability concerns, pending lawsuits, and the company's recent history of missing guidance.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors capitalize on the successful Artemis II mission and growing anticipation for the company's expanded role in the lunar economy. The community is actively debating the stock's long-term potential as a space infrastructure leader, with many discussing the interplay between recent contract awards and high volatility.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending as investors digest the recent $100 million upsized financing and look ahead to major milestones, including the completion of NEXICART-2 enrollment and a pending BLA submission. The community is actively debating the company's valuation, institutional accumulation by major funds, and the potential for a strategic partnership or buyout given the strength of NXC-201's clinical data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update PR Newswire SHELTON, Conn., March 27, 2026 Raised over $20 million in gross...

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US PR Newswire SHELTON, Conn...

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical...

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement PR Newswire SHELTON, Conn...

<ul class="summary-bullets"><li>After the adjustment, Intensity Therapeutics stock will begin trading on February 19, retaining the ticker symbol INTS.</li><li>The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million.</li><li>In January, the company said it raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027.&nbsp;</li></ul>Intensity Therapeutics, Inc. (INTS) on Friday announced a 1-for-25 reverse stock split approved by its board and shareholders, aiming to boost the per-share price of its common stock to meet Nasdaq’s minimum listing requirements.The reverse split, scheduled to take effect at 4:01 p.m. ET on February 18, will consolidate every 25 existing shares into a single new share.<h2 class="st-heading-2">Changes After The Reverse Split</h2>After the adjustment, Intensity Therapeutics stock will begin trading on February 19, under a new CUSIP number 45828J 202 while retaining the ticker symbol INTS.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/INTS">Intensity Therapeutics stock&nbsp;</a>traded 25% lower on Friday morning.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;Intensity is a late-stage biotech company developing its own cancer treatments. It uses a special drug-linking technology to create therapies that aim to destroy tumors and help the immune system better detect cancer.<h2 class="st-heading-2">Impact on Shareholders</h2>The stock consolidation will reduce the total shares outstanding from approximately 63.3 million to about 2.53 million. No fractional shares will be issued; instead, shareholders entitled to a fraction will receive cash payments based on the adjusted closing price on February 18.Alongside the split, the company will make proportional changes to stock options, warrants, convertible securities, and shares issued under its stock incentive programs. The total number of authorized shares will remain unchanged.In January, the company outlined its 2025 achievements and mapped out priorities for 2026 as it advances INT230-6, its lead cancer therapy designed to destroy tumors and stimulate immune response. Intensity raised more than $20 million in 2025, extending its cash runway into the second quarter of 2027.&nbsp;INTS stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-slips-premarket-ev-headwinds-mount-wall-street-sees-upside-physical-ai-future/cZR5NHfR4sm">Tesla Stock Slips Premarket As EV Headwinds Mount — But One Wall Street Firm Sees Over 30% Upside On A ‘Physical AI’ Future</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did INTS Stock Plummet 25% Today? 

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.

Equity

Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share.


Intensity Therapeutics Announces Reverse Stock Split

Intensity Therapeutics Announces Reverse Stock Split Intensity Therapeutics Announces Reverse Stock Split PR Newswire SHELTON, Conn., Feb. 13, 2026 Intensity's common stock is expected to begin...

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities PR Newswire SHELTON...

All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy

Intensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium...

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's...

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Current Price	$5.50
Prev Close	$5.60
Open	$5.49
Dividend Yield	0.00%
50-Day Moving Average	$7.09
Beta	0.00
Avg. Volume	27,684.28
PE Ratio	-0.47

52-Week High	$50.00
52-Week Low	$4.63
Market Capitalization	$14.23M
EPS (Annual)	-$8.56
Price to Book	1.17
Revenue Per Employee	$0.00

INTS
INTENSITY THERAPEUTICS, INC.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INTS News

INTSINTENSITY THERAPEUTICS, INC.